A new nucleosomic-based model to identify and diagnose SSc-ILD

Clinical Epigenetics

Table 1 Subjects characteristics

	SSc (n = 67)	SSc-ILD (n = 31)
Age, years	56 ± 12	60 ± 13
Gender (M/F)	17/50	6/25
BMI, kg/m²	25 ± 4	25 ± 4
Smokers (NS/FS/S) (%)	48/28/24	55/28/17
Paq-year	15 ± 17	6.9 ± 8.4
CRP	1.7 (0.7-5.1)	2.4 (1.1-6.1)
FEV1 post-BD, % pred	98 ± 22	88 ± 23*
FVC post-BD, % pred	104 ± 20	90 ± 22**
FEV1/FVC post-BD, % pred	78 ± 10	81 ± 8
TLC, % pred	101 ± 15	85 ± 19***
TLCo % pred	71 ± 20	56 ± 16**
KCO % pred	79 ± 19	74 ± 14
HRT extent (% lung)	/	5 (5-25)
IT, immunosupressive therapy (%)	14	38
OCS, oral cortico steroide (%)	24	28
Prednisolone equivalent (mg)	5 (5-5)	10 (5-10)
GI tract score, none/mild/severe (%)¹	36/62/2	16/80/4
Disease duration (year)	6.93 ± 8.47	5.55 ± 5.87
Rodnan skin score	2 (0-5)°	2 (0-4)°
limited SSc/lcSSc/dSSc/sine scleroderma (%)	38/59/6.3/4.8	41/41/14/0
Musculoskeletal involvement (%)	22	21
Renal crisis (%)	6.8	0
Cardiac involvement (%)	2	37

Data are expressed as mean ± SD
NS non-smoker, FS former smoker, S smoker, IT immunosuppressive therapy (mycophenolate mofetil, methotrexate, cyclophosphamide), SSc systemic sclerosis, lcSSc limited cutaneous, dSSc diffuse cutaneous SSc, SS sine scleroderma
°Values are expressed as mean ± SD when parametrics and median (IQR) when non parametrics
¹GI tract score, missing value: SSc 20/67; SSc-ILD 12/31
*p < 0.05
**p < 0.01
***p < 0.001 compared to healthy subjects

ISSN: 1868-7083